We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

AGILENT

Agilent provides laboratories worldwide with instruments, services, consumables, applications and expertise, enabling... read more Featured Products: More products

Download Mobile App




CD200 Expression Marks Leukemia Stem Cells in Human AML

By LabMedica International staff writers
Posted on 17 Nov 2020
Acute myeloid leukemia (AML) is organized as a hierarchy sustained by a minor population of leukemia stem cells (LSCs) with self-renewal capacity that drive disease. More...
The LSC populations of AML exhibit phenotypic, genetic, and functional heterogeneity that contribute to therapy failure and relapse.

Progress toward understanding the mechanistic basis for therapy resistance in LSCs has been hampered by difficulties in isolating cell fractions that enrich for the entire heterogeneous population of LSCs within individual AML samples. Consequently, it is critical to study the properties of all LSCs within an individual sample to develop therapies to target these disease-sustaining cells and improve patient outcomes.

Clinical Scientists at the Princess Margaret Cancer Centre (Toronto, ON, Canada) and their colleagues collected blood and bone marrow (BM) samples from newly diagnosed AML patients and BM from healthy adults. Low-density mononuclear cells (MNCs) from all samples were isolated by Ficoll density centrifugation. Lineage-negative (Lin–) cells were obtained from blood and BM using StemSep column-based isolation (Stemcell Technologies Inc, Vancouver, BC, Canada).

CD200 cell surface expression on primary AML samples was detected using purified rat anti-human CD200 and other procedures. Flow cytometry was performed using a BD LSRII, and data were analyzed by using FlowJo software (BD Biosciences, San Jose, CA, USA). The scientists also used cell sorting and xenotransplantation studies as well as analysis of NPM1 and DNMT3a mutations in lymphoid and myeloid cells from xenografts. RNA was extracted from sorted AML fractions using the RNeasy Mini/Micro Kit (Qiagen Inc, Hilden, Germany) and was quantified by using the Fragment Analyzer (Agilent Technologies, Santa Clara, CA, USA).

The team showed that show that CD200 is present on a greater proportion of CD45dim blasts compared with more differentiated CD45high cells in AML patient samples. In 49/65 (75%) of AML cases we examined, CD200 was expressed on ≥10% of CD45dim blasts; of these, CD200 identified LSCs within the blast population in 9/10 (90%) samples tested in xenotransplantation assays. CD200+ LSCs could be isolated from CD200+ normal hematopoietic stem cells (HSCs) with the use of additional markers. Notably, CD200 expression captured both CD34 and CD34+ LSCs within individual AML samples. Analysis of highly purified CD200+ LSC-containing fractions from NPM1-mutated AMLs, which are commonly CD34, exhibited an enrichment of primitive gene expression signatures compared with unfractionated cells.

The authors concluded that overall, their findings support CD200 as a novel LSC marker that is able to capture the entire LSC compartment from AML patient samples, including those with NPM1 mutation. The study was published on November 4, 2020 in the journal Blood Advances.

Related Links:
Princess Margaret Cancer Centre
Stemcell Technologies Inc
BD Biosciences
Qiagen Inc
Agilent Technologies




Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Rapid Test Reader
DIA5000
New
Host Response Immunoassay Test
MeMed BV
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.